USA flag logo/image

An Official Website of the United States Government

Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93697
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK082025
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NOVELMED THERAPEUTICS, INC.
11000 Cedar Avenue, 135 CLEVELAND, OH 44106-0000
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2009
Title: Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis
Agency: HHS
Contract: 1R43DK082025-01A1
Award Amount: $233,538.00
 

Abstract:

DESCRIPTION (provided by applicant): Approximately 400,000 people with end stage renal disease undergo hemodialysis in the United States each year. During the hemodialysis procedure, the patient's blood circulates through the dialyzer and back to the patie nt. As a result, the patient's blood encounters the artificial surfaces of the dialyzer and the tubings that connect the patient to the dialyzer. As a result, the complement alternative pathway is activated, causing generation of substantial amounts of C3a and C5a anaphylatoxins. These anaphylatoxins activate neutrophils, monocytes, and platelets, and trigger the inflammatory cascade. NovelMed has developed a monoclonal antibody, which prevents a) C3a, C5a, C5b-9, production, b) neutrophils, monocytes, and platelet activation, and c) TNF-alpha production. In this application, we propose testing the feasibility of using Bikaciomab to prevent the exacerbated inflammatory response that occurs when blood circulates through the dialyzer and associated tubing. Bas ed on current preliminary data, it is clear that Bikaciomab is a novel, target specific, and highly potent drug candidate that would prevent inflammation during dialysis. We believe that such drugs would increase the quality of life for hemodialysis patien ts. PUBLIC HEALTH RELEVANCE: Approximately 350,000 people with end stage renal disease undergo hemodialysis in the United States each year. In this already compromised patient population, virtually every patient suffers side effects from this hemodialys is procedure at one time or another due to activation of the alternate complement pathway (AP). Bikaciomab blocks the alternative pathway in blood circulating through an extra corporeal blood circulation model of hemodialysis. It is hoped that such an appr oach will eventually result in improved morbidity and mortality in the patients suffering from End Stage Kidney Failure. Public Health Relevance Statement Page 7

Principal Investigator:

Rekha Bansal
4404779874
REKHA@NOVELMED.COM

Business Contact:

Rekha Bansal
rekha@novelmed.com
Small Business Information at Submission:

NOVELMED THERAPEUTICS, INC.
NOVELMED THERAPEUTICS, INC. 2265 ENTERPRISE PKWY TWINSBURG, OH 44087

EIN/Tax ID: 421597802
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No